Skadden is representing Omrix Biopharmaceuticals, Inc. in its $438 million acquisition via a tender offer by Johnson & Johnson, announced on Nov. 24. Israel-based Omrix produces surgical products and is expected to operate as a stand-alone entity of Johnson & Johnson's subsidiary Ethicon Inc.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates